Studies Show Eli Lilly Weight-Loss Drug Helps With Sleep Apnea
By Colin Kellaher
Eli Lilly said a pair of late-stage studies showed that its blockbuster weight-loss tirzepatide significantly reduced the severity of sleep apnea in overweight adults.
The company on Wednesday said tirzepatide, which met all primary and key secondary endpoints in the Phase 3 studies, reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea and obesity.
The Indianapolis drugmaker, which markets tirzepatide for chronic weight management as Zepbound in the U.S. and Mounjaro in some international markets, said it plans to submit the study data for global regulatory reviews.
Eli Lilly, which reported more than $5 billion in combined sales of Mounjaro and Zepbound last year, said that while there are pharmaceutical treatments for the excessive sleepiness associated with obstructive sleep apnea, tirzepatide has the potential to be the first pharmaceutical treatment for the underlying disease.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 17, 2024 06:57 ET (10:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?